Site & Patient Solutions case studies

Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.

One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.

A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.

A small US based biotechnology company sought ICON’s assistance for a high-risk immunology study with heavy investment and limited resources. The study was a phase 3 Lupus SLE study with a complex protocol governing 90 sites.

A top ten pharmaceutical company needed clinical site support in an FSP model as it changed its pipeline to focus on complex oncology studies. The introduction of a Site Engagement Liaison delivered significant efficiencies and reduced risk.

A large pharma company was attempting to recruit 50 patients, including 15 treatment-naive patients, in a global study for a rare pulmonary disorder.